MOTS-c
Mitochondrial-derived peptide
MOTS-c is a 16-amino-acid peptide encoded by your own mitochondrial DNA — a 'mitochondrial-derived peptide' first identified in 2015. It's one of the most exciting research compounds in the metabolism and longevity space because it behaves like an <b>exercise mimetic</b>: it activates the same AMPK energy pathway that physical activity does. This guide covers how MOTS-c works, what the research shows, dosing references, safety and legal status.
MOTS-c quick facts
| Reported research dosing | 1mg-5mg |
| Route | Either |
| Cycle length | 4-16 Weeks |
| Frequency | 1x Daily · 5 On 2 Off or Daily |
| Half-life | Short (minutes-hours) |
| Forms | Injectable |
| Evidence level | Animal + early human |
Metabolic/energy peptide. Pre-training timing is where people feel it.
How MOTS-c works
MOTS-c's central action is activating AMPK — the cell's master 'low-energy' switch — but it does so through an elegant route: it disrupts the folate cycle (inhibiting AICAR transformylase), which causes AICAR to accumulate inside the cell, and AICAR is itself a potent AMPK activator (the same intermediate researchers use to mimic exercise in animals). Once AMPK is on, cells increase glucose uptake, ramp up fat oxidation, encourage mitochondrial biogenesis, and shut down energy-wasting pathways. MOTS-c also travels to the nucleus under stress to switch on stress-adaptation genes.
What the research shows — the 'exercise in a vial' idea
MOTS-c is naturally produced in response to exercise and stress, and its levels fall with age — which is a big part of why it's studied for metabolic and longevity applications. In animal models, MOTS-c treatment has improved endurance, enhanced fat oxidation and improved glucose metabolism and insulin sensitivity. It's important to be honest, though: MOTS-c shares key molecular signaling with exercise, but it does not replicate all the benefits of actually training — think of it as one lever exercise pulls, not a replacement for it.
The honest state of human evidence
The compelling MOTS-c data is largely preclinical (animal and cell). Human use is currently off-label and extrapolated from that animal work, without large controlled human trials behind it. It's a genuinely promising research peptide — but promising is not the same as proven, and biomarker monitoring and professional supervision matter.
MOTS-c dosing (research reference)
There is no single established MOTS-c dose — the research and practitioner literature references different strategies depending on the goal (metabolic health vs fat loss vs performance), typically as a subcutaneous injection reconstituted with bacteriostatic water. The calculator above converts a research amount into syringe units. This is a summary of existing references for education only, not dosing advice or a recommendation for human use.
Safety & side effects
As a peptide identical to one your body already makes, MOTS-c is generally described as well tolerated in the available research, but controlled long-term human safety data is lacking. Because it acts on glucose and energy metabolism, anyone with blood-sugar considerations should be especially careful, and research-market purity varies — third-party testing matters.
Related compounds
MOTS-c sits alongside other metabolic and mitochondrial tools like NAD+ and the AMPK/exercise-mimetic small molecules. It's frequently discussed in longevity and body-composition protocols rather than used in isolation.
Legal & regulatory status
MOTS-c is not FDA-approved and is sold as a research compound (research use only). Its status, like other peptides, is subject to ongoing FDA review. Follow the laws and any sport-testing rules that apply to you.
Where to get MOTS-c
Buy MOTS-c at AminoWell USA →MOTS-c reconstitution calculator
Research reconstitution calculator
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for MOTS-c
Graded by what exists behind each claim.
✅ Clinically validated
- No completed randomized human trials yet — human work is underway, so this is a statement about the calendar rather than about the molecule.
- Early human work exists on the peptide's biology — circulating MOTS-c falls with age and with insulin resistance in human cohorts — but no randomized trial of administering it.
📊 Correlative data
- Human observational data is about the ENDOGENOUS peptide, not the injected one: higher circulating MOTS-c associates with better insulin sensitivity, and one study found it elevated in long-lived Japanese cohorts. That is a correlation about your own physiology and says nothing directly about supplementing it.
- Used in practice for metabolic and endurance goals with reports of improved training capacity. Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.
🧪 Theoretical / extrapolated
- A mitochondrial-derived peptide — encoded in mitochondrial rather than nuclear DNA, which is genuinely unusual. It activates AMPK and shifts cells toward glucose utilization and fatty-acid oxidation.
- Rodent work shows improved insulin sensitivity and exercise capacity, and prevention of diet-induced obesity. The AMPK mechanism predicts the practical read: it should behave like an exercise mimetic, which means the effect is largest in someone metabolically unwell and smallest in someone already training hard.
Why an empty tier is not a verdict → · What community dosing logs are worth →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What MOTS-c actually does
MOTS-c is a peptide your mitochondria write, and that sentence is the whole reason it is interesting. It is a short open reading frame — 16 residues — encoded inside the 12S ribosomal RNA gene of mitochondrial DNA, translated from a genome that was supposed to make thirteen proteins and nothing else Zheng 2023. The class it belongs to, the mitochondrial-derived peptides, is barely fifteen years old, and MOTS-c is its best-studied member.
The signaling target is AMPK, and the route to it is the part worth being precise about. MOTS-c does not bind a cell-surface receptor that anybody has cloned. The described action is on folate-dependent one-carbon metabolism: MOTS-c inhibits flux through that pathway, purine synthesis backs up, and the intermediate AICAR accumulates. AICAR is a direct allosteric activator of AMP-activated protein kinase. So the peptide raises an endogenous AMPK activator rather than acting as one — which is a genuinely unusual mechanism and predicts that the effect should be larger where one-carbon flux is high, and larger in a cell already under energetic stress.
Downstream of AMPK the picture is conventional and reproducible. Yang 2021 reported that MOTS-c combined with exercise regulated PGC-1alpha expression, attenuated insulin resistance and improved glucose metabolism in mice, explicitly via AMPK signaling. PGC-1alpha is the master switch for mitochondrial biogenesis, so the loop closes: a peptide from the mitochondrial genome instructs the nuclear genome to build more mitochondria.
MOTS-c is a retrograde signal, and that is a different kind of drug. Almost everything in this Vault acts on a receptor at the surface of a cell. This acts in the other direction — organelle to nucleus — and Reynolds 2021 frames the consequence exactly: aging is regulated by genes encoded in both the mitochondrial and the nuclear genome. That framing, not the fat-loss marketing, is what the science is about.
One structural fact with a real consequence. The coding sequence carries a common variant, m.1382A>C, which changes residue 14 and is found in East Asian populations at meaningful frequency; the mitochondrial-microprotein literature associates such variants with athletic performance and age-related disease Kumagai 2023. Injecting a peptide that a fraction of the population does not natively make in the same form is a pharmacogenomic question nobody selling it has considered.
Cell, rodent, human — and where it stops
Step one, in cells and in mice, where the evidence is strongest. Yang 2021: MOTS-c plus an exercise intervention in mice, PGC-1alpha up, insulin resistance down, glucose metabolism improved, AMPK-dependent. Note the design — the peptide was given with exercise, and the paper's own framing is synergy.
Step two, the aging experiment, which is the best single study this compound has. Reynolds 2021 tested mice at 2, 12 and 22 months and reported enhanced physical performance across all three ages. The headline arm is the late-life one: dosing started at 23.5 months — the mouse equivalent of starting in your seventies — given intermittently, three times a week, and physical capacity and healthspan increased. An intervention that works when started late is rare and worth taking seriously.
Step three, in humans, and this is where the story turns. The same paper reports that exercise induces endogenous MOTS-c in human skeletal muscle and in the circulation Reynolds 2021, and von Walden 2021 measured it directly: acute endurance exercise raises circulating mitochondrial-derived peptides in humans. So the human data on MOTS-c is real — and it is data about your own MOTS-c going up when you train, not about an injected peptide doing anything.
The obstacle, and it is the defining one for this compound. There is no published human trial of administered MOTS-c. Not a phase 1, not a pharmacokinetic study, not a case series. Every human measurement in the literature is of the endogenous peptide as an exercise biomarker. The entire translation from "exercise raises MOTS-c and MOTS-c is good" to "injecting MOTS-c is like exercise" is unmade, and it is a large leap: a molecule released as part of a coordinated response is not the same as the same molecule injected in isolation, at a different concentration, on a different schedule, in the absence of everything else the response contained.
The second obstacle is the one the mouse paper itself names. The best rodent result used intermittent dosing, three times a week Reynolds 2021. Community practice is daily. Nobody has tested whether daily exposure to a signal that normally spikes with exercise and then falls produces the same effect, less of it, or the opposite — and receptor and pathway biology gives plenty of reason to think tonic and pulsatile signals differ.
What would have to be true, and how you would know it was not
Three predictions. The first is the one that would demonstrate the mechanism in a person, the second is the one that would show the compound is redundant with training, and the third is the one that cuts against the fat-loss marketing.
1. If AMPK activation is real at the doses used, insulin sensitivity should be the first thing to move. The whole mechanism runs AICAR to AMPK to glucose disposal Yang 2021, and the cheapest human readout is fasting insulin with glucose to compute HOMA-IR, plus HbA1c for the longer window. Baseline and 8–12 weeks. A compound activating AMPK in muscle that leaves fasting insulin unchanged has not engaged its pathway, and that is a clean falsification.
2. Hold training constant or the experiment is worthless. Exercise raises endogenous MOTS-c by itself von Walden 2021, so a person who starts the peptide and starts training has confounded the only measurement that matters. If you want to know what the injection does, keep the training block identical across the window and measure VO2 at submaximal load and grip strength at both ends — the two performance endpoints the rodent work actually moved Reynolds 2021.
3. The fat-loss claim predicts a metabolic-rate change, and it probably will not show. This is sold as a fat-loss peptide. The mechanism supports improved substrate handling and mitochondrial biogenesis; it does not obviously support appetite suppression or a large change in energy expenditure. A CMP and a lipid panel across the window are the honest supporting measurements, and if body composition changes while insulin and lipids sit still, the likely explanation is the training and the diet that came with the decision to start.
What nobody has tested yet
Four experiments nobody has run on this peptide, all of them obvious once the mechanism is written out.
Nobody has measured plasma MOTS-c after an injection in a human. The assay exists — it is the assay von Walden 2021 used to measure the exercise response. Pointing it at an injected dose would give this compound its first human pharmacokinetic data point, and the fact that the tool exists and has never been aimed here is the clearest statement of how young this field is.
Nobody has compared daily against three-times-weekly dosing. The mouse healthspan result is an intermittent-dosing result Reynolds 2021 and human practice is daily. A two-arm study with the same weekly total would test whether the schedule is the active ingredient.
Nobody has genotyped a MOTS-c cohort. The m.1382A>C variant changes the peptide itself and is common enough to stratify on Kumagai 2023. Whether carriers respond differently to the injected wild-type sequence is a question with a cheek swab attached to it and no answer.
Nobody has tested it in the population the mouse data points at. The strongest rodent result is late-life initiation in old animals Reynolds 2021. The people buying it are mostly young and training hard — the group with the highest endogenous MOTS-c and the least headroom. The trial the animal work argues for is in sedentary older adults with a physical-function endpoint, and it has never been proposed.
MOTS-c — its own safety story, not its class's
The class block above is generic to metabolic peptides. Here is what is specific.
There is no human safety data of any kind on administered MOTS-c. Not a good safety record — no record. Every human measurement in the literature is of the endogenous peptide von Walden 2021 Reynolds 2021. Statements that it is "well tolerated" come from community reports, which are real information about acute tolerability and almost none about anything else.
The mechanistic caution is AMPK, and it is a real one. AMPK activation is the same axis metformin and AICAR act on, and it is not a uniformly benign axis: AMPK activation blunts mTOR signaling, which is the pathway muscle protein synthesis runs through. Taking an AMPK activator around a training block aimed at hypertrophy is mechanistically self-defeating, and that tension has never been measured for this peptide in either species. Named here as extrapolation from pathway biology, not as an observed effect.
The second mechanistic caution is glucose, in one specific situation. An AMPK-dependent improvement in glucose disposal Yang 2021 is the desired effect in an insulin-resistant person and a stacking hazard in someone already on a glucose-lowering agent. Nobody has run that combination in a study, so the interaction is inferred rather than observed — which is a reason for a glucose meter, not a reason for reassurance.
The purity question is sharper here than for most peptides. A 16-residue peptide is easy to synthesize and easy to get subtly wrong, and because there is no clinical assay in routine use and no established response marker, a person taking an incorrect sequence has no way to find out. For most compounds the answer is "watch the marker". Here there is no marker.
Sources read for this page
- Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications 2021 · PMID 33473109
- von Walden F, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. Journal of Applied Physiology 2021 · PMID 34351816
- Kumagai H, et al. Novel Insights into Mitochondrial DNA: Mitochondrial Microproteins and mtDNA Variants Modulate Athletic Performance and Age-Related Diseases. Genes (Basel) 2023 · PMID 36833212
- Yang B, et al. MOTS-c interacts synergistically with exercise intervention to regulate PGC-1alpha expression, attenuate insulin resistance and enhance glucose metabolism in mice via AMPK signaling pathway. Biochimica et Biophysica Acta - Molecular Basis of Disease 2021 · PMID 33722744
- Zheng Y, et al. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology 2023 · PMID 36761202
MOTS-c — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These act on mitochondrial function, NAD+ availability, sirtuin signaling or cellular clearance. The honest prediction is that acute harm is unlikely and the interesting risks are theoretical and long-range — which is a different shape of risk, not an absence of one.
- Growth and clearance signals cut both ways. Anything that improves the efficiency of cell survival is also improving it for cells you would rather not keep. Anything that pushes clearance hard is doing so indiscriminately.
- The near-term, practical ones: NAD+ precursors and infusions commonly cause flushing and a strong sensation if pushed fast, and several compounds in this class are stimulating enough to disrupt sleep.
What has actually been reported
- Generally well tolerated at studied doses. NAD+ infusion discomfort is rate-dependent and resolves by slowing down.
- The human evidence is mostly short trials with surrogate endpoints — a marker moved, not a life changed. That is worth knowing before you build a decade-long habit on it.
How to reduce the risk
Same mechanism as the prediction.
- Slow the infusion rate. Almost all NAD+ discomfort is rate, not dose. There is no prize for finishing quickly.
- Dose earlier in the day. Several of these are subtly stimulating, and sleep is where most of the repair you are paying for happens.
- Pick an endpoint you can actually measure, and take the baseline before you start. This is the class most prone to spending years on something with no way of knowing whether it did anything.
- Fix the basics first. Sleep, training and bloodwork move the same markers further than anything on this list, and they are free. A longevity compound stacked on four hours of sleep is a rounding error.
What it does to your bloodwork
A fact about the assay.
- There is no NAD+ assay worth ordering clinically. Judge this class on downstream markers — inflammatory markers, lipids, fasting glucose, and whatever your baseline panel showed as out of range.
Don't run this if
- Active malignancy, for the survival-signaling reasoning above.
- Pregnancy — uncharacterized.
The honest unknown
- Whether any of it extends healthspan in humans. Every honest person in this field is running on mechanism and animal data, and this catalog should say so rather than imply otherwise.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Close to the tissue, and consistency beats the clock — fasted
A brief exposure starts a process that runs for days, so the hour you dose is a minor variable — missing days is the one that costs you. Where the target is local, dosing near the site is worth more than any timing choice.
The fasted flag on this one is real: food blunts absorption enough to matter.
From half-life and route, not a dosing trial.
MOTS-c — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What MOTS-c moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
Where these work, systemic inflammation is the plausible readout.
What to do: hs-CRP is cheap and moves. Baseline and 12 weeks. - HbA1c (Hemoglobin A1c) — ↓ expected to fall
Improved mitochondrial and metabolic function should show here if the effect is real at all.
What to do: The honest use of these markers is as a falsification test: if nothing moves in 12 weeks, the compound is not doing much for you. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver and kidney function — the standard baseline for anything run long term.
What to do: Twice a year is enough on a stable protocol.
This class is where honest expectation-setting matters most: the markers above are how you find out whether anything happened, and for most of these compounds that question is genuinely open.
Everything on this page, in an order
This one is free and stays free. What Skool adds is the rest of the shelf — 278 compounds and 371 supplements with the protocol, the stack order and the bloodwork to run beside it.
Join Skool — $10/mo →Bloodwork to run alongside MOTS-c
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | A mitochondrial peptide aimed squarely at metabolic health |
| Fasting Insulin | Where the effect should appear first |
| Comprehensive Metabolic Panel (CMP) | Fasting glucose, liver and kidney |
| hs-CRP (High-Sensitivity C-Reactive Protein) | Inflammation baseline |
The Metabolic Health & Prediabetes panel covers these in one order — 8 markers, $81.45 with the discount applied.
Check results you already have → · All 103 markers A–Z
MOTS-c — frequently asked questions
What is MOTS-c?
MOTS-c is a 16-amino-acid mitochondrial-derived peptide, encoded by mitochondrial DNA and discovered in 2015. It's researched for metabolism, insulin sensitivity and as an 'exercise-mimetic' compound.
How does MOTS-c work?
It activates AMPK — the cell's energy-sensing switch — by causing AICAR to accumulate, which boosts glucose uptake, fat oxidation and mitochondrial biogenesis, mirroring some of exercise's molecular signaling.
Is MOTS-c really 'exercise in a vial'?
It shares key signaling with exercise (AMPK activation) and improved endurance and fat oxidation in animals, but it does not replicate all of exercise's benefits. It's a research tool, not a replacement for training.
Does MOTS-c work in humans?
Most evidence is preclinical (animal/cell). Human use is off-label and extrapolated, without large controlled human trials, so it should be treated as an experimental research peptide with proper monitoring.
How is MOTS-c dosed?
There's no single established dose; the literature references different strategies by goal, as a subq injection reconstituted with bacteriostatic water (see the calculator above). This is educational, not dosing advice.
Is MOTS-c FDA-approved?
No. MOTS-c is not FDA-approved and is sold as a research compound, with status subject to ongoing FDA review.
References & further reading
MOTS-c inside a finished plan
One arm of 5 Protocol Blueprints, free to read in full.
What MOTS-c is used for
MOTS-c appears under 5 goals in the goal router.
Related Metabolic & Fat Loss compounds
Where this goes next
MOTS-c is the mitochondrial arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.